Daewon Pharmaceutical complies with 11 out of 15 (73.3%) corporate governance key indicators, maintaining a generally stable governance structure.
Major shareholder and related parties hold 37.08%, while minority shareholders hold 47.85%, indicating high minority ownership requiring attention to voting rights and information fairness.
On a consolidated basis, the company recorded revenue of 605.4B KRW, operating profit of 3.5B KRW, and a net loss of 4.0B KRW. Despite weak profitability, it maintained a cash dividend of 250 KRW per share (yield 2.1%), demonstrating commitment to shareholder returns.
The dividend policy mandates returning at least 15% of net income (individual basis) per the articles of incorporation, but the dividend record date is not pre-determined, leaving room for improvement in predictability.
The board consists of 3 inside directors and 3 outside directors (experts in accounting, pharmacy, and law), but all are male, raising diversity concerns; the company plans to recruit candidates from diverse backgrounds.
The audit committee is composed entirely of outside directors to ensure independence, and it holds quarterly meetings with external auditors without management presence, enhancing audit transparency.
There is a 12B KRW convertible bond (conversion price 12,893 KRW), which is above the current market price (8,730 KRW), limiting dilution risk. A call option of 3B KRW is in place for the major shareholder to stabilize control.
A CEO succession policy was established in October 2024, with candidate management and training ongoing, but early-stage effectiveness evaluation is needed.
[AI Summary]Daewon Pharmaceutical's corporate governance report shows a 73% compliance rate, which is satisfactory, but areas for improvement include dividend predictability and board gender diversity. The decision to maintain dividends despite a net loss signals shareholder commitment, yet the lack of share buybacks or cancellations limits the scope of return policies. Overall investment risk is low, but governance improvements are unlikely to significantly impact stock price in the near term.